Azurity patents expiration
1. Edarbi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(1 year, 3 months from now) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(4 years from now) | |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
EDARBI family patents
2. Edarbyclor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(1 year, 3 months from now) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(4 years from now) | |
| US9169238 | AZURITY | Solid pharmaceutical composition |
Feb, 2030
(6 years from now) | |
| US9387249 | AZURITY | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
Jul, 2031
(7 years from now) | |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
Market Authorisation Date: 20 December, 2011
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
EDARBYCLOR family patents
3. Epaned patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9808442 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US10786482 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US10154987 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US9669008 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US10772868 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US11040023 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US11141405 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US11173141 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US10039745 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
Drugs and Companies using ENALAPRIL MALEATE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: Method of treatment of heart failure; Treatment of heart failure; Method of treating hypertension; Method of treating left ventricular dysfunction; Treatment of hypertension
Dosage: SOLUTION;ORAL
EPANED family patents
4. Eprontia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11633374 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(16 years from now) | |
| US11433046 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(16 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 05 November, 2021
Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age ...
Dosage: SOLUTION;ORAL
EPRONTIA family patents
5. Firvanq Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959949 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
| US10959948 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
| US10688046 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
| US10959946 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
| US10493028 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
| US11638692 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
| US10959947 | AZURITY | Composition and method for vancomycin oral liquid |
Mar, 2035
(11 years from now) | |
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 26 January, 2018
Treatment: Treatment of c. difficile-associated diarrhea; Treatment of staphylococcal enterocolitis
Dosage: FOR SOLUTION;ORAL
FIRVANQ KIT family patents
6. Fleqsuvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446246 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(13 years from now) | |
| US11324696 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(14 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 04 February, 2022
Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis
Dosage: SUSPENSION;ORAL
FLEQSUVY family patents
7. Horizant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(10 months ago) | |
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(1 year, 6 months from now) | |
| US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(1 year, 3 months from now) | |
| US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(2 years from now) | |
| US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(5 years from now) | |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
Market Authorisation Date: 06 April, 2011
Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; Management of postherpetic neuralgia (phn) in adults
Dosage: TABLET, EXTENDED RELEASE;ORAL
HORIZANT family patents
8. Katerzia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10894039 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US10959991 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US11701326 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US10952998 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US11364230 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US11484498 | AZURITY | NA |
Oct, 2037
(14 years from now) | |
| US11471409 | AZURITY | NA |
Oct, 2037
(14 years from now) | |
| US10695329 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US10799453 | AZURITY | Amlodipine formulations |
Apr, 2039
(15 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: Treatment of hypertension; Method of treating hypertension; Angina pectoris; Angina; A method of treating coronary artery disease; A method of treating hypertension
Dosage: SUSPENSION;ORAL
KATERZIA family patents
9. Konvomep patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103492 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US10751333 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US11633478 | AZURITY | Compositions and kits for Omeprazole suspension |
Jul, 2039
(15 years from now) | |
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
KONVOMEP family patents
10. Nymalize patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7070581 | AZURITY | Dispenser for medicaments and method and apparatus for making same |
Jun, 2023
(3 months ago) | |
| US8517997 | AZURITY | Dispenser for medicaments and method and apparatus for making same |
May, 2024
(7 months from now) | |
| US10342787 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(14 years from now) | |
| US11517563 | AZURITY | NA |
Apr, 2038
(14 years from now) | |
| US11413277 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(14 years from now) | |
| US11207306 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(14 years from now) | |
| US10576070 | AZURITY | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(14 years from now) | |
Drugs and Companies using NIMODIPINE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...
Dosage: SOLUTION;ORAL
NYMALIZE family patents
11. Qbrelis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9814751 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10265370 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US9616096 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10039800 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10406199 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US9463183 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US11179434 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10940177 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
Drugs and Companies using LISINOPRIL ingredient
Market Authorisation Date: 29 July, 2016
Treatment: Treatment of hypertension; Method of treating hypertension; Treatment of heart failure; Treatment of myocardial infarction; Reduction of mortality in acute myocardial infarction; Acute myocardial infa...
Dosage: SOLUTION;ORAL
QBRELIS family patents
12. Sotylize patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206895 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(10 years from now) | |
| US11013703 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(10 years from now) | |
| US9724297 | AZURITY | Sotalol compositions and uses of the same |
Aug, 2035
(11 years from now) | |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2014
Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently ...
Dosage: SOLUTION;ORAL
SOTYLIZE family patents
13. Xatmep patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10231927 | AZURITY | Methotrexate composition |
Jan, 2033
(9 years from now) | |
| US10610485 | AZURITY | Methotrexate composition |
Jan, 2033
(9 years from now) | |
| US9855215 | AZURITY | Methotrexate composition |
Jan, 2033
(9 years from now) | |
| US9259427 | AZURITY | Methotrexate composition |
Jan, 2033
(9 years from now) | |
| US11116724 | AZURITY | Methotrexate composition |
Jan, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 25, 2024 |
Drugs and Companies using METHOTREXATE SODIUM ingredient
Market Authorisation Date: 25 April, 2017
Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis
Dosage: SOLUTION;ORAL
XATMEP family patents
14. Zonisade patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478456 | AZURITY | NA |
Aug, 2038
(14 years from now) | |
| US11529333 | AZURITY | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
Aug, 2038
(14 years from now) | |
Drugs and Companies using ZONISAMIDE ingredient
Market Authorisation Date: 15 July, 2022
Treatment: A method of treating seizures
Dosage: SUSPENSION;ORAL
ZONISADE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic